KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ionis Pharmaceuticals (IONS) Shares Outstanding (2016 - 2025)

Ionis Pharmaceuticals (IONS) has 17 years of Shares Outstanding data on record, last reported at $161.1 million in Q3 2025.

  • For Q3 2025, Shares Outstanding rose 2.11% year-over-year to $161.1 million; the TTM value through Sep 2025 reached $161.1 million, up 2.11%, while the annual FY2024 figure was $157.9 million, 9.4% up from the prior year.
  • Shares Outstanding reached $161.1 million in Q3 2025 per IONS's latest filing, up from $159.2 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $161.1 million in Q3 2025 and bottomed at $140.9 million in Q1 2021.
  • Average Shares Outstanding over 5 years is $147.0 million, with a median of $143.2 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding: rose 0.57% in 2022, then grew 10.06% in 2024.
  • A 5-year view of Shares Outstanding shows it stood at $141.2 million in 2021, then grew by 0.6% to $142.1 million in 2022, then grew by 1.61% to $144.3 million in 2023, then rose by 9.4% to $157.9 million in 2024, then grew by 2.04% to $161.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding were $161.1 million in Q3 2025, $159.2 million in Q2 2025, and $159.0 million in Q1 2025.